• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma.

作者信息

Leng Siyang, Bhutani Divaya, Raza Shahzad, Assal Amer, Pan Samuel, Hu Jianhua, Wei Alexander, Mapara Markus, Lentzsch Suzanne

机构信息

Division of Hematology/Oncology, Columbia University Irving Medical Center, 161 Fort Washington Ave, New York, NY, 10032, USA.

Saint Luke's Health System, 4321 Washington St Ste 4000, Kansas City, MO, 64111, USA.

出版信息

Blood Cancer J. 2020 Feb 3;10(2):13. doi: 10.1038/s41408-020-0278-5.

DOI:10.1038/s41408-020-0278-5
PMID:32015343
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6997347/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3181/6997347/4da8439e1d6d/41408_2020_278_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3181/6997347/21f3a4b0f67c/41408_2020_278_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3181/6997347/4da8439e1d6d/41408_2020_278_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3181/6997347/21f3a4b0f67c/41408_2020_278_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3181/6997347/4da8439e1d6d/41408_2020_278_Fig2_HTML.jpg

相似文献

1
Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma.卡非佐米、苯达莫司汀和地塞米松（CBD）用于新诊断多发性骨髓瘤患者的I/II期研究。
Blood Cancer J. 2020 Feb 3;10(2):13. doi: 10.1038/s41408-020-0278-5.
2
Bendamustine and dexamethasone are an effective salvage regimen for patients with advanced multiple myeloma in a Home Care Unit program.
Leuk Lymphoma. 2016 Jul;57(7):1716-8. doi: 10.3109/10428194.2015.1106531. Epub 2015 Dec 23.
3
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.每周一次的卡非佐米、泊马度胺和低剂量地塞米松用于复发/难治性骨髓瘤：一项I/II期研究。
Leukemia. 2018 Aug;32(8):1803-1807. doi: 10.1038/s41375-018-0024-1. Epub 2018 Jan 30.
4
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.复发多发性骨髓瘤患者中卡非佐米与地塞米松联合用药对比硼替佐米与地塞米松联合用药：3期研究ENDEAVOR（NCT01568866）按年龄亚组划分的结果
Leuk Lymphoma. 2017 Oct;58(10):2501-2504. doi: 10.1080/10428194.2017.1298755. Epub 2017 Mar 17.
5
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.苯达莫司汀、硼替佐米和地塞米松作为老年多发性骨髓瘤患者二线治疗的II期研究：法语国家骨髓瘤研究组2009-01试验
Haematologica. 2015 Feb;100(2):e56-9. doi: 10.3324/haematol.2014.110890. Epub 2014 Nov 14.
6
Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.新诊断多发性骨髓瘤患者接受卡非佐米、来那度胺和地塞米松治疗的缓解率和无进展生存期：一项 2 期临床试验的 5 年随访结果。
JAMA Oncol. 2018 Dec 1;4(12):1781-1783. doi: 10.1001/jamaoncol.2018.5457.
7
Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.苯达莫司汀、泊马度胺和地塞米松用于复发和/或难治性多发性骨髓瘤
Blood Cancer J. 2018 Jul 31;8(8):71. doi: 10.1038/s41408-018-0104-5.
8
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.苯达莫司汀、低剂量地塞米松和来那度胺（BdL）用于治疗复发/难治性多发性骨髓瘤患者的I/II期研究证实了非常有前景的结果。
Leuk Lymphoma. 2017 Mar;58(3):552-559. doi: 10.1080/10428194.2016.1205741. Epub 2016 Jul 21.
9
Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.苯达莫司汀-来那度胺-地塞米松及苯达莫司汀-硼替佐米-地塞米松联合方案用于晚期多发性骨髓瘤的活性及毒性特征
Leuk Lymphoma. 2014 May;55(5):1191-3. doi: 10.3109/10428194.2013.820289. Epub 2013 Aug 13.
10
Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy.硼替佐米、来那度胺和地塞米松治疗初治多发性骨髓瘤患者的临床研究
Br J Haematol. 2017 Apr;177(2):254-262. doi: 10.1111/bjh.14536. Epub 2017 Feb 7.

引用本文的文献

1
Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group.基于苯达莫司汀的方案作为难治性/复发性多发性骨髓瘤患者的挽救疗法：波兰骨髓瘤小组的回顾性真实世界分析
J Clin Med. 2021 Nov 24;10(23):5504. doi: 10.3390/jcm10235504.
2
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.复发/难治性多发性骨髓瘤的新兴疗法：嵌合抗原受体T细胞疗法及其他。
J Hematol Oncol. 2021 Jul 23;14(1):115. doi: 10.1186/s13045-021-01109-y.
3
Current and Novel Alkylators in Multiple Myeloma.

本文引用的文献

1
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.苯达莫司汀、硼替佐米和泼尼松用于治疗新诊断的多发性骨髓瘤患者：一项西班牙/PETHEMA前瞻性2期试验的结果
Haematologica. 2015 Aug;100(8):1096-102. doi: 10.3324/haematol.2015.124818. Epub 2015 Apr 24.
多发性骨髓瘤中的当前及新型烷化剂
Cancers (Basel). 2021 May 18;13(10):2465. doi: 10.3390/cancers13102465.
4
A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma.卡非佐米、苯达莫司汀和地塞米松用于复发和/或难治性多发性骨髓瘤的I期试验。
Am J Hematol. 2021 Jul 1;96(7):E243-E246. doi: 10.1002/ajh.26178. Epub 2021 May 6.